<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377076</url>
  </required_header>
  <id_info>
    <org_study_id>526.005</org_study_id>
    <nct_id>NCT02377076</nct_id>
  </id_info>
  <brief_title>Dietary Calcium Supplementation, Gut Permeability and Microbiota in Type 2 Diabetics</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Vicosa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do estado de Minas Gerais</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of Vicosa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dietary calcium seems to act on glycemic control, favoring the prevention and treatment of&#xD;
      type 2 diabetes mellitus (DM2). It is possible that calcium modulates gut microbiota and&#xD;
      increase the integrity of the intestinal mucosa. This study aims to evaluate the effects of&#xD;
      dietary calcium supplementation in permeability and intestinal microbiota in overweight type&#xD;
      2 diabetics. This is a single-blind, randomized, placebo-controlled, crossover study.&#xD;
      Patients (n=20) with low habitual calcium intake will be allocated in control group (CONTROL)&#xD;
      or test group (DAIRY). Hypocaloric diets (restriction of 500 kcal / day) will be prescribed&#xD;
      containing 800 mg of calcium from dietary sources / day. During intervention period, a&#xD;
      beverage (shake) (CONTROL - without the addition of calcium sources or DAIRY - 700 mg of&#xD;
      calcium as milk powder) will be ingested in the laboratory. Food intake, body composition&#xD;
      (total body fat and fat free mass) and anthropometric measures (waist circumference,&#xD;
      waist-hip ratio, waist-height, neck circumference and sagittal abdominal diameter) will be&#xD;
      evaluated at baseline and at the 6th and 12th weeks. Physical activity level, gut&#xD;
      permeability, gut microbiota, and biochemical parameters (parathyroid hormone, 25-dihydroxy&#xD;
      vitamin D, calcium, fasting glucose, fasting insulin, fructosamine, hemoglobin, HbA1c, uric&#xD;
      acid, triglycerides, cholesterol total and partial, lipopolysaccharide, inflammatory markers)&#xD;
      will be evaluated at baseline and after 12 weeks. The statistical analysis will be performed&#xD;
      with the use of SPSS software (SPSS Inc., Chicago, IL, 2008, version 17.0). Parametric or&#xD;
      non-parametric tests will be applied, according to the distribution of variables (level of&#xD;
      statistical significance of 5%).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>DAIRY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary calcium supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary calcium supplementation</intervention_name>
    <description>Dietary calcium supplementation as milk powder</description>
    <arm_group_label>DAIRY</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Control (Whey protein, vitamin D, sugar and salt)</description>
    <arm_group_label>CONTROL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes mellitus using oral hypoglycemic medication&#xD;
&#xD;
          -  Overweight (body mass index between 25 and 34.9 kg / m2)&#xD;
&#xD;
          -  Usual intake of calcium less than 600 mg / day&#xD;
&#xD;
          -  Level of physical activity light to moderate&#xD;
&#xD;
          -  HbA1c above 7% or fasting glucose above 130 mg / dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Use of calcium, vitamin D, magnesium, zinc, chromium, copper supplements or medication&#xD;
             affecting the metabolism of these micronutrients,&#xD;
&#xD;
          -  Use of drugs, herbs or diets that reduce appetite and body weight&#xD;
&#xD;
          -  Estrogen replacement&#xD;
&#xD;
          -  Gain or loss of at least 5 kg in the last 3 months&#xD;
&#xD;
          -  Recent change in the level of physical activity&#xD;
&#xD;
          -  Aversion or intolerance to food provided in the study&#xD;
&#xD;
          -  Alcohol consumption of more than 2 doses / day (more than 50g ethanol / day)&#xD;
&#xD;
          -  Eating disorders&#xD;
&#xD;
          -  Endocrine disease, renal disease, hepatic disease or malabsorption syndrome that&#xD;
             alters calcium metabolism&#xD;
&#xD;
          -  History of recurrent nephrolithiasis&#xD;
&#xD;
          -  Caffeine consumption of&gt; 300 mg / day&#xD;
&#xD;
          -  Pregnancy, lactation or postmenopausal&#xD;
&#xD;
          -  Anemia&#xD;
&#xD;
          -  Cardiovascular, infectious, inflammatory, thyroid, liver, kidney or intestinal disease&#xD;
&#xD;
          -  Use of anti-inflammatory, antacids, antibiotics and laxatives drugs&#xD;
&#xD;
          -  Major gastrointestinal surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Metabolism and body composition laboratory, Federal University of Vicosa</name>
      <address>
        <city>Viçosa</city>
        <state>Minas Gerais</state>
        <zip>36570-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>February 25, 2015</study_first_submitted>
  <study_first_submitted_qc>March 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>February 3, 2018</last_update_submitted>
  <last_update_submitted_qc>February 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Vicosa</investigator_affiliation>
    <investigator_full_name>Dr Junia Maria Geraldo Gomes</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

